Pharma Mar SAU
Research Pharma Mar SAU (PMRA) on Bullrun: market cap EUR 1.42B, P/E 25.5, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPMRA
- ExchangeF
- CountrySpain
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.42B
- P/E25.5
- Dividend yield1.2%
- Financial periodQ1 2026
- RevenueEUR 42.90M
- Net incomeEUR 1.53M
- Free cash flowEUR 7.24M
- Gross margin91.5%
Valuation Snapshot
latest market cap is EUR 1.42B; P/E is 25.5; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 25.5x versus a Healthcare sector median of 24.46x (4.2% above).
Latest dividend yield is 1.2% versus a Healthcare sector median of 2.11% (43.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | EUR 174.86M | EUR 26.13M | -EUR 8.99M | 95.3% | 1.49 | EUR 63.24M | EUR 39.87M | EUR 208.36M |
| FY2023 | EUR 158.15M | EUR 1.14M | -EUR 28.25M | 93.9% | 0.06 | EUR 60.02M | EUR 27.04M | EUR 193.44M |
| FY2022 | EUR 196.34M | EUR 49.36M | n/a | 93.1% | 2.73 | EUR 149.81M | EUR 25.88M | EUR 222.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 1.42B | 25.5 | 1.2% | 1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1 EUR, yield 1.2%.
| Year | Dividends/share |
|---|---|
| FY2024 | 0.65 EUR |
| FY2023 | 0.65 EUR |
| FY2022 | 0.65 EUR |
About Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pharma Mar SAU's market cap?
Pharma Mar SAU's market capitalization is EUR 1.42B.
What is Pharma Mar SAU's P/E ratio?
Pharma Mar SAU's price-to-earnings (P/E) ratio is 25.5.
Does Pharma Mar SAU pay a dividend?
Pharma Mar SAU has a dividend yield of 1.2%.
What does Pharma Mar SAU do?
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments.